Other B-cell Lymphomas

This page covers rare B-cell lymphoma subtypes — mantle cell lymphoma (MCL), Burkitt lymphoma, post-transplant lymphoproliferative disorder (PTLD), HIV-associated lymphoma, and primary CNS lymphoma — whose treatment landscapes differ substantially from DLBCL and follicular lymphoma. Key agents include BTK inhibitors and CAR-T (brexucabtagene autoleucel) for MCL, high-dose methotrexate for PCNSL, DA-EPOCH-R for Burkitt, and rituximab-based approaches for PTLD.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Other B-cell Lymphomas

• Rituximab (Rituxan) — Monoclonal Antibody
• Ibrutinib (Imbruvica) — Tyrosine Kinase Inhibitor
• Acalabrutinib (Calquence) — BTK Inhibitor
• Zanubrutinib (Brukinsa) — BTK Inhibitor
• Pirtobrutinib (Jaypirca) — BTK Inhibitor
• Brexucabtagene autoleucel (Tecartus) — Other
• Venetoclax (Venclexta) — BCL-2 Inhibitor
• Bendamustine (Treanda) — Alkylating Agent
• Cyclophosphamide (Cytoxan) — Alkylating Agent
• Doxorubicin (Adriamycin) — Anthracycline
• Vincristine (Oncovin) — Vinca Alkaloid
• Methotrexate (Trexall) — Antimetabolite
• Etoposide (VePesid) — Topoisomerase Inhibitor
• Cytarabine (Cytosar-U) — Antimetabolite